查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1542709

POC 血脂檢測的全球市場

POC Lipid Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球 POC 血脂檢測市場預計將達到 3.271 億美元

全球POC血脂檢測市場預估2023年為2.633億美元，預估至2030年將達3.271億美元，2023年至2030年複合年成長率為3.1%。高血脂症應用是本報告分析的細分市場之一，預計複合年成長率為 2.9%，到分析期結束時將達到 9,700 萬美元。在分析期間，高三酸甘油脂血症應用領域的複合年成長率估計為4.1%。

美國市場預估為6,920萬美元，中國預期複合年成長率為5.4%

預計2023年美國POC血脂檢測市場規模將達6,920萬美元。中國作為世界第二大經濟體，預計2023年至2030年複合年成長率為5.4%，預計2030年市場規模將達到7,050萬美元。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 0.9% 和 2.4%。在歐洲，德國的複合年成長率預計為 1.5%。

全球 POC 血脂檢測市場 – 主要趨勢和促進因素總結

即時 Health Insight POC 血脂測試的作用

照護現場(POC) 血脂檢測是指在患者照護端直接測量血脂水平的過程，無需集中檢測設施即可提供即時結果。此測試通常測量關鍵的脂質參數，例如總膽固醇、高密度脂蛋白 (HDL)、低密度脂蛋白 (LDL) 和三酸甘油酯，這些參數對於評估心血管健康至關重要。 POC 血脂檢測設備通常使用從手指刺穿處抽取的少量血液。將血液塗布測試條或盒，並使用比色測定和生物感測器等方法在可攜式設備中進行分析。快速的結果使醫療保健提供者能夠快速做出臨床決策，加強患者管理，並促進血脂異常症和其他脂質相關疾病的早期療育。

POC血脂檢測如何應用於臨床？

在臨床實踐中，POC血脂檢測在常規健康檢查和慢性病管理中發揮重要作用。基層醫療醫師可以在例行檢查期間使用這些測試來監測患者的血脂水平，以及早發現高血脂症和其他心血管危險因子。對於已知患有血脂異常症的患者，POC 測試提供了一種便捷的方法來追蹤治療效果並根據需要調整藥物。在緊急情況下，快速血脂檢測可以幫助對急性冠狀動脈症候群和其他心血管事件的患者進行風險分層。此外，POC 血脂檢測在偏遠和資源有限的地區（檢測設施可能受到限制）非常有價值，可確保患者獲得基本的診斷服務。 POC 血脂檢測的即時和便利性使其成為現代醫療保健的重要工具，特別是在需要快速臨床判斷的情況下。

POC血脂檢測技術的發展趨勢是什麼？

支援 POC 血脂檢測的技術不斷發展，力求變得更準確、更易於使用，並且更能融入更廣泛的醫療保健系統。一個顯著的趨勢是測試設備的小型化和便攜化。測試設備變得越來越小且更易於使用，更容易在各種醫療保健環境中使用。生物感測器技術的進步提高了這些儀器的靈敏度和特異性，使它們能夠產生更可靠的結果。與數位健康平台的整合也是一個關鍵趨勢，可以將測試結果自動上傳到電子健康記錄(EHR)、遠端監控和遠端醫療應用程式。此外，人們對開發多分析 POC 設備越來越感興趣，這些設備可以同時評估多個健康參數並提供患者心血管健康的更全面的資訊。這些創新使 POC 血脂檢測變得更加便利、高效且資訊豐富，從而改善了患者照護和管理。

推動POC血脂檢測市場成長的因素有哪些？

POC 血脂檢測市場的成長受到多種因素的推動，反映出對快速、可靠的診斷工具的需求不斷成長。心血管疾病盛行率的上升和世界對預防性醫療保健的重視是重要的促進因素，因為早期發現和管理血脂異常症對於降低心血管風險至關重要。 POC 測試設備的技術進步，包括更高的準確性、便攜性以及與數位醫療系統的整合，正在增強其在各種醫療保健環境中的採用。遠端醫療和遠端患者監護的使用增加，特別是為了應對 COVID-19 大流行，也推動了對 POC 血脂檢測的需求，以支持患者照護的連續性，而無需頻繁的親自就診。此外，對個人化醫療的日益關注正在推動 POC 測試的使用，該測試可根據即時血脂水平評估提供量身定做的治療計劃。這些因素共同確保了 POC 血脂檢測市場的強勁成長，凸顯了其在現代醫療保健和慢性病管理中的重要角色。

受訪企業範例（共42例）

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Abaxis, Inc.
  • Accutech LLC
  • Alere, Inc.
  • Biochemical Systems International Srl
  • Bio-Rad Laboratories, Inc.
  • Eurotrol BV
  • F. Hoffmann-La Roche AG
  • General Life Biotechnology Co., Ltd.
  • Helena Laboratories Corporation
  • Nova Biomedical Corporation

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP14040

Global POC Lipid Testing Market to Reach US$327.1 Million by 2030

The global market for POC Lipid Testing estimated at US$263.3 Million in the year 2023, is expected to reach US$327.1 Million by 2030, growing at a CAGR of 3.1% over the analysis period 2023-2030. Hyperlipidemia Application, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$97.0 Million by the end of the analysis period. Growth in the Hypertriglyceridemia Application segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$69.2 Million While China is Forecast to Grow at 5.4% CAGR

The POC Lipid Testing market in the U.S. is estimated at US$69.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$70.5 Million by the year 2030 trailing a CAGR of 5.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global POC Lipid Testing  Market - Key Trends and Drivers Summarized

Instant Health Insights: The Role of POC Lipid Testing

Point-of-care (POC) lipid testing refers to the process of measuring lipid levels directly at the site of patient care, providing immediate results without the need for centralized laboratory facilities. This testing typically measures key lipid parameters, including total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides, which are critical for assessing cardiovascular health. POC lipid testing devices often use small blood samples obtained through a finger prick. The blood is applied to a test strip or cassette, which is then analyzed by a portable device using methods such as colorimetric assays or biosensors. The rapid turnaround of results allows healthcare providers to make prompt clinical decisions, enhancing patient management and facilitating early intervention in cases of dyslipidemia and other lipid-related disorders.

How Is POC Lipid Testing Utilized in Clinical Practice?

In clinical practice, POC lipid testing plays a crucial role in both routine health assessments and the management of chronic conditions. Primary care physicians use these tests during regular check-ups to monitor patients' lipid levels, enabling the early detection of hyperlipidemia and other cardiovascular risk factors. For patients with known lipid disorders, POC testing provides a convenient way to track treatment efficacy and adjust medications as needed. In emergency settings, rapid lipid testing can aid in the risk stratification of patients presenting with acute coronary syndromes or other cardiovascular events. Furthermore, POC lipid testing is invaluable in remote and resource-limited settings where access to laboratory facilities may be restricted, ensuring that patients still receive essential diagnostic services. The immediacy and convenience of POC lipid testing make it an indispensable tool in modern healthcare, particularly in scenarios requiring swift clinical decisions.

What Are the Current Trends in POC Lipid Testing Technology?

The technology behind POC lipid testing is continually advancing, driven by the need for greater accuracy, ease of use, and integration with broader healthcare systems. One notable trend is the miniaturization and portability of testing devices, which are becoming increasingly compact and user-friendly, facilitating their use in various healthcare environments. Advances in biosensor technology are enhancing the sensitivity and specificity of these devices, ensuring more reliable results. Integration with digital health platforms is another significant trend, allowing for the automatic upload of test results to electronic health records (EHRs) and enabling remote monitoring and telemedicine applications. Additionally, there is growing interest in developing multi-analyte POC devices that can assess multiple health parameters simultaneously, providing a more comprehensive overview of a patient’s cardiovascular health. These innovations are making POC lipid testing more accessible, efficient, and informative, improving overall patient care and management.

What Factors Are Driving the Growth in the POC Lipid Testing Market?

The growth in the POC lipid testing market is driven by several factors, reflecting the increasing demand for rapid and reliable diagnostic tools. The rising prevalence of cardiovascular diseases and the global emphasis on preventive healthcare are significant drivers, as early detection and management of lipid disorders are critical for reducing cardiovascular risk. Technological advancements in POC testing devices, including improved accuracy, portability, and integration with digital health systems, are enhancing their adoption across various healthcare settings. The expanding use of telemedicine and remote patient monitoring, especially in response to the COVID-19 pandemic, is also boosting demand for POC lipid testing, as it supports ongoing patient care without the need for frequent in-person visits. Additionally, the growing focus on personalized medicine is encouraging the use of POC testing to provide tailored treatment plans based on real-time lipid level assessments. These factors collectively ensure robust growth in the POC lipid testing market, underscoring its vital role in modern healthcare and chronic disease management.

Select Competitors (Total 42 Featured) -

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Abaxis, Inc.
  • Accutech LLC
  • Alere, Inc.
  • Biochemical Systems International Srl
  • Bio-Rad Laboratories, Inc.
  • Eurotrol B.V.
  • F. Hoffmann-La Roche AG
  • General Life Biotechnology Co., Ltd.
  • Helena Laboratories Corporation
  • Nova Biomedical Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • POC Lipid Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Global Economic Update
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for POC Lipid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Hyperlipidemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Hyperlipidemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Hyperlipidemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Hypertriglyceridemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Hypertriglyceridemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Hypertriglyceridemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Familial Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Familial Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Familial Hypercholesterolemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Hyperlipoproteinemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Hyperlipoproteinemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Hyperlipoproteinemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Tangier Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Tangier Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Tangier Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World POC Lipid Testing Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: China 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for POC Lipid Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: France Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: France 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Germany 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Italy 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: UK 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 53: Spain Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Spain Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Spain 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Russia Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Russia 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 59: Rest of Europe Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Rest of Europe Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Rest of Europe 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for POC Lipid Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Asia-Pacific 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 68: Australia Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Australia Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Australia 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • INDIA
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 71: India Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: India Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: India 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 74: South Korea Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: South Korea Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: South Korea 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 77: Rest of Asia-Pacific Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Rest of Asia-Pacific Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Rest of Asia-Pacific 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for POC Lipid Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Latin America 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 86: Argentina Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Argentina Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Argentina 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 89: Brazil Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Brazil Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Brazil 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 92: Mexico Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Mexico Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Mexico 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 95: Rest of Latin America Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Latin America Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Latin America 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for POC Lipid Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for POC Lipid Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for POC Lipid Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Middle East 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 104: Iran Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Iran Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Iran 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 107: Israel Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Israel Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Israel 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 110: Saudi Arabia Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Saudi Arabia Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Saudi Arabia 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 113: UAE Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UAE Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UAE 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 116: Rest of Middle East Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Middle East Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Middle East 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030
  • AFRICA
    • POC Lipid Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 119: Africa Recent Past, Current & Future Analysis for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Africa Historic Review for POC Lipid Testing by Application - Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Africa 16-Year Perspective for POC Lipid Testing by Application - Percentage Breakdown of Value Sales for Hyperlipidemia, Hypertriglyceridemia, Familial Hypercholesterolemia, Hyperlipoproteinemia, Tangier Disease and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION